166 related articles for article (PubMed ID: 16564077)
1. Follow-up of ovarian and primary peritoneal carcinoma: the value of physical examination in patients with pretreatment elevated CA125 levels.
Menczer J; Chetrit A; Sadetzki S; Golan A; Levy T
Gynecol Oncol; 2006 Oct; 103(1):137-40. PubMed ID: 16564077
[TBL] [Abstract][Full Text] [Related]
2. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
Juretzka MM; Barakat RR; Chi DS; Iasonos A; Dupont J; Abu-Rustum NR; Poynor EA; Aghajanian C; Spriggs D; Hensley ML; Sabbatini P
Gynecol Oncol; 2007 Jan; 104(1):176-80. PubMed ID: 16996584
[TBL] [Abstract][Full Text] [Related]
3. CA125 nadir concentration is an independent predictor of tumor recurrence in patients with ovarian cancer: a population-based study.
van Altena AM; Kolwijck E; Spanjer MJ; Hendriks JC; Massuger LF; de Hullu JA
Gynecol Oncol; 2010 Nov; 119(2):265-9. PubMed ID: 20797777
[TBL] [Abstract][Full Text] [Related]
4. Value of serum CA125 levels in patients with high-risk, early stage epithelial ovarian cancer.
Kang WD; Choi HS; Kim SM
Gynecol Oncol; 2010 Jan; 116(1):57-60. PubMed ID: 19818996
[TBL] [Abstract][Full Text] [Related]
5. CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan.
Gossner G; Coleman RL; Mutch DG; Horowitz NS; Rader JS; Gibb RK; Powell MA; Herzog TJ
Gynecol Oncol; 2006 Oct; 103(1):212-8. PubMed ID: 16677696
[TBL] [Abstract][Full Text] [Related]
6. The role of regular physical examination in the detection of ovarian cancer recurrence.
Chan KK; Tam KF; Tse KY; Ngan HY
Gynecol Oncol; 2008 Aug; 110(2):158-61. PubMed ID: 18544459
[TBL] [Abstract][Full Text] [Related]
7. The lack of significance of Ca125 response in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debulking.
Le T; Hopkins L; Faught W; Fung-Kee-Fung M
Gynecol Oncol; 2007 Jun; 105(3):712-5. PubMed ID: 17400284
[TBL] [Abstract][Full Text] [Related]
8. Follow-up of patients treated by cytoreduction and chemotherapy for peritoneal carcinomatosis of colorectal origin.
Verwaal VJ; Zoetmulder FA
Eur J Surg Oncol; 2004 Apr; 30(3):280-5. PubMed ID: 15028309
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of rising serum CA-125 levels within the normal range in patients with epithelial ovarian, primary peritoneal, and tubal cancers, who, after initial treatment, had a complete clinical response.
Levy T; Weiser R; Boaz M; Shem EB; Golan A; Menczer J
Int J Gynecol Cancer; 2012 Oct; 22(8):1344-8. PubMed ID: 22954785
[TBL] [Abstract][Full Text] [Related]
10. Circulating CA125 in patients with peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion.
Baratti D; Kusamura S; Martinetti A; Seregni E; Oliva DG; Laterza B; Deraco M
Ann Surg Oncol; 2007 Feb; 14(2):500-8. PubMed ID: 17151789
[TBL] [Abstract][Full Text] [Related]
11. CA125 based diagnosis and therapy in recurrent ovarian cancer.
Meier W; Baumgartner L; Stieber P; Hasholzner U; Fateh-Moghadam A
Anticancer Res; 1997; 17(4B):3019-20. PubMed ID: 9329590
[TBL] [Abstract][Full Text] [Related]
12. The significance of the pattern of serum CA125 level ascent to above the normal range in epithelial ovarian, primary peritoneal and tubal carcinoma patients.
Levy T; Weiser R; Boaz M; Ben Shem E; Golan A; Menczer J
Gynecol Oncol; 2013 Apr; 129(1):165-8. PubMed ID: 23274778
[TBL] [Abstract][Full Text] [Related]
13. [Clinical value of the estimation of growth kinetics of primary ovarian cancer recurrences by CA125 doubling time].
Riedinger JM; Coudert B; Barillot I; Buffenoir G; Mayer F; Fargeot P; Cuisenier J; Guerrin J
Bull Cancer; 1997 Sep; 84(9):855-60. PubMed ID: 9435806
[TBL] [Abstract][Full Text] [Related]
14. [Clinical value of serum CA19-9, CA125 and CP2 in mucinous ovarian tumor: a retrospective study of 273 patients].
Dong L; Cui H; Li XP; Sun LF; Chang XH; Liang XD; Zhu HL
Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):5-8. PubMed ID: 18366923
[TBL] [Abstract][Full Text] [Related]
15. [Successful treatment of primary peritoneal carcinoma with paclitaxel and carboplatin combination chemotherapy].
Tohya T; Ujioka T; Yamaguchi M
Gan To Kagaku Ryoho; 2008 Jan; 35(1):153-5. PubMed ID: 18195548
[TBL] [Abstract][Full Text] [Related]
16. Prolonged symptom-free survival in a patient with persistent primary peritoneal carcinoma and a rising CA-125: a note of caution.
Markman M
Gynecol Oncol; 2001 Jun; 81(3):509-11. PubMed ID: 11371148
[TBL] [Abstract][Full Text] [Related]
17. Metastatic colorectal adenocarcinoma involving the ovary with elevated serum CA125: a potential diagnostic pitfall.
Lewis MR; Euscher ED; Deavers MT; Silva EG; Malpica A
Gynecol Oncol; 2007 May; 105(2):395-8. PubMed ID: 17335881
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival.
Alberts DS; Marth C; Alvarez RD; Johnson G; Bidzinski M; Kardatzke DR; Bradford WZ; Loutit J; Kirn DH; Clouser MC; Markman M;
Gynecol Oncol; 2008 May; 109(2):174-81. PubMed ID: 18314182
[TBL] [Abstract][Full Text] [Related]
19. The value of serum and tissular expression of CA 125 antigen, in evaluation of the response to second line chemotherapy for the relapsed ovarian carcinoma.
Bădulescu F; Bădulescu A; Schenker M; Popescu CF; Stoica Z
Rom J Morphol Embryol; 2005; 46(4):329-34. PubMed ID: 16688372
[TBL] [Abstract][Full Text] [Related]
20. [Relationship between CA125 half life during neoadjuvant chemotherapy and the optimal operation rate and prognosis in patients with advanced epithelial ovarian carcinoma].
Xi XW; Wan XP; Li SD; Sun TW; Zhu YP
Zhonghua Fu Chan Ke Za Zhi; 2006 Feb; 41(2):91-4. PubMed ID: 16640855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]